AbbVie and Iambic have entered into a multiyear collaboration to accelerate AI-driven drug discovery across immunology, neuroscience, and oncology. The partnership will combine Iambic’s molecular superintelligence platform with AbbVie’s drug discovery expertise to identify and develop small molecule therapies with first-in-class and best-in-class potential.
Under the agreement, Iambic will receive an upfront payment and will be eligible for success-based milestone payments and tiered royalties on net sales of products resulting from the collaboration. The companies did not disclose the upfront payment, potential milestone value, or other financial terms.
The partnership will focus on applying artificial intelligence to one of the most complex aspects of pharmaceutical research: identifying molecules that demonstrate the biological activity and other characteristics required for successful drug development.
Traditional small molecule discovery requires scientists to evaluate numerous properties of each potential drug candidate, often through separate rounds of computational analysis, chemical synthesis, and laboratory testing.
This process can be time-consuming because optimizing one molecular property may negatively affect another. Researchers must balance multiple requirements when designing compounds that are sufficiently effective, selective, and suitable for further development.
Iambic’s platform is designed to address these challenges by optimizing multiple molecular properties simultaneously, allowing researchers to evaluate a broader range of potential drug candidates and make more informed decisions earlier in the discovery process.
The collaboration will use Iambic’s Enchant and NeuralPLexer technologies, which combine AI-driven molecular modeling with experimental data to support drug discovery and development.
A central component of the partnership will be Enchant v3, Iambic’s next-generation multimodal transformer model. The technology integrates biomedical data from different stages of drug discovery and enables researchers to test multiple drug design hypotheses in parallel.
Enchant v3 has been trained on more than 6,000 molecular properties and is designed to improve prediction accuracy across drug discovery and development.
By incorporating information from multiple biomedical data sources, the model aims to provide a more comprehensive understanding of the characteristics that influence a potential drug candidate’s performance.
This approach is intended to help scientists prioritize compounds with desirable combinations of properties, reduce the number of unsuccessful candidates pursued during research, and shorten the time required to identify promising molecules.
For AbbVie, the agreement expands its use of specialized artificial intelligence tools within its pharmaceutical research operations.
The company is integrating AI across its organization through AI@AbbVie, an enterprise-wide initiative focused on scientific innovation, operational efficiency, and improved decision-making.
The initiative includes applications across research and development, business operations, and other functions involved in discovering, developing, and delivering medicines.
The partnership with Iambic will give AbbVie’s discovery scientists access to AI technologies specifically designed to address molecular design challenges.
AbbVie intends to combine these capabilities with its established scientific expertise in immunology, neuroscience, and oncology, three therapeutic areas that form a significant part of its drug development strategy.
Rather than replacing laboratory research or scientific judgment, the collaboration is designed to provide researchers with additional computational tools to evaluate potential treatments and prioritize promising candidates.
The companies will pursue drug discovery programs with the potential to produce both first-in-class medicines, which introduce new therapeutic approaches, and best-in-class medicines, which seek to improve upon existing treatments.
For Iambic, the agreement provides an opportunity to apply its technology alongside an established pharmaceutical research organization while expanding the use of its AI platform beyond its internal drug development programs.
The clinical-stage company has developed an integrated approach combining proprietary AI technology with automated, scalable chemistry and biology experimentation.
Its platform is intended to create a continuous relationship between computational predictions and experimental results, allowing information generated in the laboratory to inform subsequent molecular designs.
Iambic has demonstrated its platform’s capabilities by advancing a novel drug candidate into clinical development in approximately two years. The company has also established a diversified preclinical pipeline.
Through the AbbVie partnership, Iambic will apply its molecular modeling and predictive technologies to additional drug discovery challenges while supporting the development of potential new therapies.
The collaboration reflects both companies’ efforts to incorporate AI more extensively into pharmaceutical research, with the goal of improving the efficiency of molecular design and increasing the likelihood that promising compounds progress through development.
KEY QUOTES:
“We are excited about the purpose-built AI capabilities Iambic is bringing to our Discovery scientists. We believe AI will be a powerful catalyst for scientific innovation across AbbVie. By equipping our teams with fit-for-purpose AI solutions, we can accelerate discovery, expand what is possible in R&D and significantly advance our commitment to making a remarkable impact for patients.”
Nicholas Donoghoe, M.D., Executive Vice President And Chief Business And Strategy Officer At AbbVie
“Combining Iambic’s platform with the drug-hunting expertise of AbbVie scientists can help us make more precise decisions about the molecules we pursue. The goal of our collaboration with Iambic is to design better molecules more efficiently and improve our probability of success, ultimately to deliver breakthrough medicines for patients sooner.”
Jonathon Sedgwick, Ph.D., Senior Vice President And Global Head Of Discovery Research At AbbVie
“Iambic’s mission is to make better technology for better medicines — in our own hands and with partners. We are eager to bring Iambic’s molecular superintelligence platform to bear alongside AbbVie’s world-class team to address unmet patient need. We anticipate an impactful collaboration — for Iambic, for AbbVie, and for the patients we serve.”
Tom Miller, Ph.D., Co-Founder And CEO Of Iambic
